Once again, Medtronic pays millions of dollars
Covidien, a subsidiary of Medtronic, has agreed to pay almost $20 million to settle allegations by the DOJ that the company violated the anti-kickback statute of the False Claims Act when it induced California- and Florida-based health providers to purchase its ClosureFast radiofrequency ablation catheters from 2011 to 2014. This is not the first time Medtronic paid millions to settle allegations, as the company agreed to pay $51 million for introducing an adulterated medical device into interstate commerce in 2018, and agreed to pay $12 million for deceptively marketing one of its devices known as Infuse.

Related Posts
April 15, 2021
Cala Health Claims to Have the only Patented Neurostimulation for Essential Tremor Treatment. The Patent Data Disagrees
Cala Health has figured out that innovations backed by patents make them exponentially more valuable in the marketplace. However, in a zest…
AI Biotech / Diagnostics,AI Biotech / Diagnostics: Activity,AI Biotech / Diagnostics: Neurology
April 8, 2021
Capital One is Investing in AI Biotech? What’s in their wallet?
In the past 18 months, Capital One has expanded past its usual banking activities, and begun exploring the AI Biotech Sector. But do they…
April 1, 2021
Google AI Reinvents Speech Recognition. Who will follow?
There is no doubt that the big 5 tech companies (Apple, Amazon, Google, Facebook, and Microsoft) have developed massive IP portfolios in…
AI Biotech / Diagnostics,AI Biotech / Diagnostics: Neurology


